Janssen, LP
164
8
27
99
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 40/100
11.0%
18 terminated/withdrawn out of 164 trials
84.6%
-1.9% vs industry average
32%
53 trials in Phase 3/4
25%
25 of 99 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (164)
Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma
Role: collaborator
CAR-T Cell Therapy in RelApsed/Refractory Myeloma With ExtrameduLlary Disease - an in Vivo Imaging and Molecular Monitoring Study
Role: collaborator
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001
Role: collaborator
Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL
Role: collaborator
Novel Treatments in Improving Renal Outcomes in Light Chain Cast Nephropathy
Role: collaborator
Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer
Role: collaborator
Evolution of the Therapeutic Care in Lung Cancer in France Since 2015 (ESME LC)
Role: collaborator
Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects
Role: collaborator
Efficacy and Safety of Carfilzomib in Combination With Ibrutinib vs Ibrutinib in Waldenström's Macroglobulinemia
Role: collaborator
A Physical Activity Program to Improve Quality of Life and Reduce Fatigue in Metastatic Breast Cancer
Role: collaborator
Daratumumab Combined With Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting With Extramedullary Disease
Role: collaborator
Neo-adjuvant Abiraterone Prostate Study
Role: collaborator
Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alterations
Role: collaborator
Computerized Decision Support to Prevent Stroke in Atrial Fibrillation
Role: collaborator
Study of Daratumumab Combined With Carfilzomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma
Role: collaborator
National Register of Actionable Mutations
Role: collaborator
European Myeloma Network (EMN) Sample Project
Role: collaborator
Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction
Role: collaborator
An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma
Role: collaborator
Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma
Role: collaborator